Avoid the trap of trying to achieve everything with one launch. Instead, define a single primary KPI—such as press mentions, sales rep message adoption, or a specific user action—and build the entire campaign strategy around optimizing for that one goal.

The commercial success curve of a new drug is locked in within the first six to nine months post-launch. After this point, market perceptions are set, and additional investment yields diminishing returns. A rapid, real-time feedback loop is crucial for course-correction *during* this make-or-break period.

Metrics like "Marketing Qualified Lead" are meaningless to the customer. Instead, define key performance indicators around the value a customer receives. A good KPI answers the question: "Have we delivered enough value to convince them to keep going to the next stage?"

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Proving the ROI of clinical AI can take years if based solely on patient outcomes. Instead, focus on early, measurable operational wins that are known proxies for better care. Track metrics like increased clinician capacity and higher patient engagement rates to prove the system's value and build momentum.

To prove business impact beyond vanity metrics, define success by aligning with key departments *before* the campaign starts. Executives want pipeline, product wants trials, and customer success wants retention. This prevents a disconnect where marketing celebrates impressions while leadership asks about revenue.

Many biotechs focus R&D solely on regulatory approval. Beren Therapeutics integrates commercial thinking early to ensure clinical development answers a different question: Is what we're building meaningful to patients, payers, and providers? This de-risks the asset for commercial success, not just clinical milestones.

During a product launch, top-line revenue can be a lagging indicator. The most critical real-time metric is sessions. If site traffic is significantly below forecast, it is the earliest and most urgent sign of a problem, allowing for quicker intervention.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.